Philips paves the way for faster lung cancer diagnosis and treatment with advanced 3D imaging and navigation platform
September 21 2020 - 9:00AM
September 21, 2020
Philips Azurion Lung Edition supports high precision diagnosis
and minimally invasive therapy in one room
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
introduced Azurion Lung Edition, an advanced 3D imaging and
navigation platform to accelerate the diagnosis and treatment of
lung cancer. The suite combines CT-like 3D images acquired at the
tableside (Cone Beam CT) with live X-ray guidance and advanced
tools to support image-guided lung procedures. The system is
designed specifically for bronchoscopy procedures, enabling
clinicians to perform both minimally invasive endobronchial
biopsies and lesion ablation during the same procedure. By speeding
diagnosis and treatment, Azurion Lung Edition is helping to
transform lung cancer care, contributing to dramatically improved
outcomes and reduced costs.
Each year 1.7 million people die worldwide of lung cancer,
making it the leading cause of cancer deaths globally [1] and
accounting for more loss of life than breast, colon and prostate
cancer combined. Today, over 60% of patients are diagnosed at a
late stage, with a small chance of a surgical cure. But thanks to a
rise in the number of lung cancer screening programs and increasing
patient awareness, a growing proportion of patients have small
peripheral lesions that are operable.
In addition to early diagnosis, fast treatment is critical to
ensure better outcomes and quality of life for lung cancer
patients, with every week of delay resulting in a 5% increase in
mortality [2]. Today, most patients face a long journey to a
definitive diagnosis and they often undergo a painful recovery
after open surgery. Cone Beam CT is seen as the gold standard for
clinicians to both diagnose and treat lung cancer in one room, and
even during the same procedure.
“This is a very exciting time in the world of interventional
pulmonology and advanced bronchoscopy,” said Dr. Michael Pritchett,
pulmonary and critical care physician, Director, Chest Center of
the Carolinas, FirstHealth Moore Regional Hospital, Pinehurst
Medical Clinic, U.S. “One of the things that we’re particularly
excited about is being able to diagnose patients, stage their
cancer and treat them, all in a single procedure. As a diagnostic
bronchoscopist it’s exciting and rewarding to be able not only to
diagnose patients, but to go on to treat them as well.”
“Lung cancer is one of the most aggressive forms of cancer, and
we need innovative technology to fight back,” said Dr. Gustavo
Cumbo-Nacheli, Director of Bronchoscopy and Interventional
Pulmonology at Spectrum Health in Grand Rapids, Michigan, U.S.
“Without a Cone Beam CT scan to confirm placement of the biopsy
needle, repeat procedures are often necessary. And by combining
Cone Beam CT with other technologies, including robotics, we will
be able to go beyond biopsy and treat the patient.”
On Wednesday, September 23 at 13:00 ET (19:00 CET). Dr. Atul
Gupta, Interventional Radiologist and Chief Medical Officer,
Philips Image Guided Therapy, will host an exclusive virtual
roundtable together with a panel of renowned pulmonologists and
interventional radiologists, “The Future Now: Implementing
Cone Beam CT-guided endobronchial ablation therapy”. To
register, click here.
“Image-guided minimally invasive procedures continue to expand
into new treatment areas, enabled by sophisticated,
procedure-oriented solutions like Azurion Lung Edition,” said Dr.
Gupta. “With lung cancer increasingly being detected at an earlier
stage, new minimally invasive treatment strategies like ablation
have the potential to significantly improve outcomes for
patients.”
Intuitive, integrated and efficient, the Azurion platform
optimizes clinical and operational lab performance and expands the
role of image-guided interventions in the treatment of patients.
The platform has achieved rapid global adoption and has been used
in well over two million procedures [3] worldwide.
Philips Azurion Lung Edition is available now in the U.S.
[1] American Cancer Society: Cancer Facts & Figures 2013.
[2] Kanarek et al., Survival after community diagnosis of
early-stage non-small cell lung cancer. The American journal of
medicine. 127, no. 5 (2014): 443-449.[3] Based on Philips’ internal
case and procedure data.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email:
mark.groves@philips.comTwitter: mark_groves
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.comTwitter: FC_Feer
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips-Azurion-lung-ablation
- Philips-Azurion-Lung-Edition
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2023 to Apr 2024